


PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 33/24		A1	(11) International Publication Number: WO 99/64019
			(43) International Publication Date: 16 December 1999 (16.12.99)
(21) International Application Number: PCT/US99/13112		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 10 June 1999 (10.06.99)			
(30) Priority Data: 09/095,565 11 June 1998 (11.06.98) US			
(71) Applicant: VIRGINIA COMMONWEALTH UNIVERSITY [US/US]; Dr. Richard Franson, Office Technology Transfer, 1101 East Marshall Street, MCV Campus, P.O. 980568, Richmond, VA 23298-0568 (US).			
(72) Inventors: FARRELL, Nicholas; 102 North Stafford Avenue, Richmond, VA 23220 (US). BIERBACH, Ulrich; 2000 Riverside Drive 14G, Richmond, VA 23225 (US).			
(74) Agent: WHITHAM, Michael; Whitham, Curtis & Whitham, Suite 900, 11800 Sunrise Valley, Reston, VA 20191 (US).		Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	

(54) Title: PLATINUM COMPLEXES WITH ANTI-VIRAL ACTIVITY AND METHOD OF USING SAME



(57) Abstract

The present invention relates to treatment of viral infections, such as HIV, with a new class of anti-viral platinum coordination compound having the general structural formula $[PtX_mB_{3-m}]$ where X is an anionic ligand, A is an acyclic, nitrogen containing monodentate ligand such as amines, ammines, and quinolines, and B is nucleobase.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

WO 99/64019

PCT/US99/13112

1

**PLATINUM COMPLEXES WITH
ANTI-VIRAL ACTIVITY AND
METHOD OF USING SAME**

5

DESCRIPTION

BACKGROUND OF THE INVENTION

(1) *Field of the Invention*

10

The invention is generally related to platinum complexes having anti-viral activity and methods of using them for treating patients, including both humans and animals, with viral infections.

(2) *Background Information*

15

Platinum complex compounds have been proposed for use in pharmaceutical compositions for several types of medical treatments on animals.

20

For instance, US Pat. 4,177,263 teaches the use of various platinum (II) and (IV) coordination compounds, such as chloroplatinumammines, for treatment of malignant tumors in animals. US Pat. 5,562,925 is related to US Patent 4,177,263.

25

US Pat. 5,225,207 teaches Pt complexes for pharmaceutical applications in treatment of cancers, in which amino-groups of a Pt(II) complex, e.g., a chloroplatinumammine derivative, form a part of the same heterocyclic ring including the Pt atom.

US Pat. 5,275,827 teaches a platinum (II) complex useful as an anti-tumor agent in which the bidentate amine is retained in the formula while a heterocyclic sulphonyl carboxylate group is formed in lieu of the other two

WO 99/64019

PCT/US99/13112

2

donor ligands and the heterocyclic ring includes the Pt atom as a ring atom.

US Pat. 5,665,343 teaches an anticancer agent that is polymeric platinum (II) complex in which a bioactive diamineplatinum (II) moiety is incorporated into a polyphosphazene backbone of a polymer chain.

5 US Pat. 4,053,587 teaches a method for treating animals afflicted with a viral infection with certain types of platinum coordination compounds of the formulae described therein. The preferred compounds are described as being cis-Pt(II)(NH₃)₂Cl₂ complexes, cis-Pt(IV)(NH₃)₂Cl₄ complexes, and cis-Pt(II)(H₂O)₂(NH₃)₂ complexes. The '587 patent also teaches certain
10 trans-Pt(IV) compounds, as well as certain malonato platinum (II) and (IV) coordination compounds.

Although some advances have been made, there still remains a major need in the health field to develop and identify new compounds that have significant anti-HIV activity. As known, the HIV (human immunodeficiency
15 virus), formerly referred to as HTLV-III, is a retrovirus that is the etiologic agent of AIDS (acquired immunodeficiency syndrome). As known, AIDS is a disease that compromises the competency of the immune system, characterized by persistent lymphadenopathy and various opportunistic
20 infections, such as *Pneumo-cystiscarnii* pneumonia, cytomegalovirus, disseminated histoplasmosis, candidiasis, and isosporiasis, and so forth. In view of these pervasive effects on the body, the development of new drugs that will effectively treat an HIV-infected patient has been a challenging undertaking.

25

BRIEF SUMMARY OF THE INVENTION

The present invention satisfies the above and other objectives as it relates to effectively treating viral infections, such as HIV, with a new class of platinum compounds.

WO 99/64019

PCT/US99/13112

3

More particularly, the present invention relates to a method for preventing viral infections of a patient involving administering to the patient an effective anti-viral amount of a platinum coordination complex. The anti-HIV activity of platinum compounds of this invention has been
5 experimentally established and confirmed by studies that are described in the examples herein.


BRIEF DESCRIPTION OF THE DRAWING

10 FIG. 1 is a graph showing the results of *in vitro* anti-HIV activity of a platinum complex of the invention.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS OF THE INVENTION

15 The present invention relates to relieving and preventing viral infection in a host or patient. In particular, the method comprises administering to a host or patient an amount of a compound having the general structural formula:

20



25 X is an anionic ligand such as halogens (Cl, Br, I, or F), NO₃, ClO₄, hydroxyl OH, alkoxide OR, sulfhydryl SH or SR, where R is preferably a substituted or unsubstituted alkyl moiety (C₁₋₁₂ is preferred). Chloride is the preferred anionic ligand. A is an ammine (NH₃ linked directly to the platinum metal), a secondary or tertiary amine substituted with alkyl moieties, or a substituted or unsubstituted heterocyclic amine. The preferred heterocycles may include thiazole, benzothiazole, imidazole, isoquinoline, and quinoline; however
30 other useful heterocycles which may include oxazole, indole, and acridine.

WO 99/64019

PCT/US99/13112

An example of a substituted heterocycle would include 4-Mepyrizidine. In the case where multiple A constituents are present, the constituents may be the same or different (e.g., all amines or heterocyclic amines, etc.). B can be the same as A. For example, one compound within the family defined by the

5 general structure noted above would be $[PtCl(NH_3)_3]^+$. However, it is preferred that B be a nitrogen containing nucleobase where the nitrogen is connected to the Pt moiety. Examples of nucleobases include purine and purine type compounds (guanine, adenine, hypoxanthine, xanthine, uric acid, caffeine, threobromine, etc.), pyrimidines (uracil, thymine, cytosine,

10 methylcytosine, etc.) and pyrimidine derivatives (thiamine, etc.), nucleosides (guanosine, etc.), nucleotides (5'-guanosinemonophosphate, etc.), and oligonucleotide or defined polynucleotide sequences (e.g., an extension of deoxyribonucleic acid (DNA), ribonucleic acid (RNA) or peptidonucleic acids (PNA)). The preferred binding site of endocyclic nitrogens is N7 for



15 purines and N3 for pyrimidines. Examples of compounds within the practice of this invention include $Trans[PtCl(9-ethylguanine-N7)(NH_3)_2]NO_3$, and $Trans[PtCl(9-ethylguanine-N7)(NH_3)(quinoline)]$. The structures of these compounds are set forth below as structures 1 and 2, respectively, and the synthesis and antiviral (particularly anti-HIV) activity is discussed in the

20 Examples.

25

5

5



It should be noted that B is a monodentate, nitrogen containing,
heterocyclic moiety in Structures one and 2. In the case of nucleosides,
nucleotides, and DNA, RNA, or PNA sequences, the Pt would be linked to
the nitrogen of a nucleotide in the sequence in a manner similar to that
shown above in the two chemical structures. Other exemplary structures
which should be useful within the practice of this invention include trans-
[PtCl(pyridine)₂(9-ethylguanine)]⁺, trans-[PtCl(thiazole)₂(9-ethylguanine)]⁺,
and [PtCl(NH₃)(pyridine)(9-ethylguanine)]⁺.

Under the general structural formula noted above, there can be more
than one B substituent, and, in these cases, the B substituents can be the
same or different. In addition, under the general structural formula, m
ranges between 0 and 3, whereby there may be as many as three A
substituents or three B substituents connected to the Pt. Thus, it will be
understood by those of skill in the art that compounds within this invention
can have as many as three different N-containing heterocycles, or have as
many as three identical N-containing heterocycles, as the B substituents.
Platinum (II) forms dsp² complexes which are generally planar. The
geometry of [PtXA_mB_{3-m}] may either be cis or trans for X related to B. As is
shown in the two above-identified structures, the preferred embodiment has
the anionic ligand trans to the nucleobase (e.g., Cl trans to 9-Ethylguanine).

The platinum compounds of formula of the present invention, each of
which has at least one ligand thereof formed of heterocyclic ring including N

WO 99/64019

PCT/US99/13112

6

as a ring member, can be synthetically derived from a haloplatinumammine starting compound. Haloplatinumammine compounds, such as cis or trans-Pt(II)(NH₃)₂Cl₂, can be synthesized by well known methods, such as described in the textbook references listed at col. 3, lines 45-59 of U.S. Pat. No. 4,053,587, which teachings are incorporated by reference. In any event, the haloplatinumammine compound, such as cis or trans-Pt(II)(NH₃)₂Cl₂, is dissolved in an organic solvent, such as an aprotic solvent of dimethylformamide (DMF) or dimethylsulfoxide (DMSO), and then reacting the haloplatinumammine compound with AgNO₃ to precipitate AgCl. After filtering off the AgCl, the filtrate will be mixed with a heterocyclic compound including a nitrogen in a ring member thereof which will form a Pt-ligand bond assuming the position of the Cl atom eliminated from the complex in the previous reaction step, and the mixture is permitted to react over an extended period time with stirring. The solvent (e.g., DMF) is then removed by volatilizing it to yield a crystalline product.

To provide a platinum compound of this invention having a second ligand constituted by a heterocyclic compound including a nitrogen in a ring member thereof, it is merely necessary to repeat the above reaction scheme on the Pt complex reaction product derived from the first run through the synthesis procedure except, in the second run, introducing the second heterocyclic compound desired for the second ligand in the reaction step of precipitating AgCl. It is understood that in providing a Pt complex with two ligands that are heterocyclic groups including a N atom in the ring in this manner, that the starting haloplatinumammine compound will need to have two halo groups available for the overall reaction.

While a cis or trans-Pt(II)(NH₃)₂Cl₂ compound has no charge, it is understood that other chloroplatinumammine compounds also could be used as a starting material in the above reaction scheme, even if they bear a charge. For example, trichloroamineplatinate (II) has a (-) charge while

WO 99/64019

PCT/US99/13112

7

chlorotriamineplatinum (II) has a (+) charge. These chloroplatinumammine compounds exist in the solid state as salts in conjunction with appropriate oppositely charged ions, e.g., positively charged Pt complexes are generally prepared as nitrates or halides while negatively charged Pt complexes are generally prepared as ammonium or alkali metal salts.

Likewise, it should be understood that the compounds of the present invention $[PtXA_mB_{3-m}]$, which are administered to a patient for antiviral applications, particularly including anti-HIV treatment, can be charged or uncharged. For example, the molecule $PtCl(NH_3)_3^+$ has a positive charge. Charged compounds can be put in the form of salts by association with oppositely charged ions. For example, structures one and two above are associated with nitrate ions. As discussed above in conjunction with the starting materials, the Pt complexes of this invention can take the form of solid state salts where the positively charged Pt complexes will generally take the form of nitrates or halides while negatively charged Pt complexes are generally prepared as ammonium or alkali metal salts.

The platinum complexes used in the Examples reported herein were prepared, and purified by crystallization and stored in the dark until needed for testing. Test solutions were freshly prepared immediately prior to use by dissolving the test complex in physiological saline.

The pharmaceutical compositions of the present invention including the platinum coordination complex compounds described herein can be used with suitable pharmaceutically acceptable carriers. Where the composition is adapted for parenteral administration, the platinum coordination compounds may be dissolved or suspended in a suitable carrier liquid such as physiological saline, buffered saline, distilled water, and so forth. It will be understood that where the pharmaceutical compositions contemplated by this invention are intended for intravenous administration that the platinum compounds will be introduced in solution form. Where the platinum

compounds described herein are intended for intramuscular or subcutaneous administration, they can be administered in either solution or suspension form.

5 Many other modes of administration may also be employed for the platinum compounds of this invention, and these will necessitate the use of different carriers, adjuvants, elixirs, and the like. For example, the compounds can be suspended in chlorofluorocarbon or hydrofluorocarbon propellants for delivery via inhaler to the lungs. Alternatively, the platinum compounds could be formulated in a matrix (lactose, etc.) or carrier (e.g.,
10 liposomes, etc.) which will allow delivery orally, sublingually or by suppository.

The administration of pharmaceutical compositions of the present invention can be intermittent, or at a gradual, or continuous, constant or controlled rate to a patient (human or animal). In addition, the time of day
15 and the number of times per day that the pharmaceutical formulation is administered can vary. The host or patient for the therapeutic treatment using the platinum compounds described herein generally are mammalian, such as humans, dogs, and rodents, and so forth. The effective dose can vary depending upon factors such as the mode of delivery; sex, age, and
20 other conditions of the patient; and the severity of the viral infection.

Generally, for parenteral administration in humans, dosages in the range of from about 0.1 to about 500 mg active Pt compound/kg body weight/24 hr., more preferably 1.0 to 10.0 mg active Pt compound/kg body weight/24 hr., for a patient afflicted with the viral infection is generally
25 effective. The level of efficacy and optimal amount of dosage for any given platinum complex of this invention can vary one from the other depending on the virus being treated.

The pharmaceutical compositions including the platinum complex agents of this invention also can include pharmaceutically acceptable

WO 99/64019

PCT/US99/13112

9

additives or adjuncts to the extent that they do not hinder or interfere with the therapeutic effect desired of the Pt complex anti-viral agent. Examples of these could include preservatives (e.g., benzalkonium chloride, methyl paraben, etc.); colorants; surfactants (TWEEN, oleic acid, etc.); and binders or encapsulants (lactose, liposomes, etc.).

In the following examples, objects and advantages of this invention are further illustrated by various embodiments thereof but the details of those examples should not be construed to unduly limit this invention.

All parts and percentages in the examples are by weight unless otherwise indicated.

EXAMPLES

Example 1:

Trans[PtCl(9-ethylguanine-N7)(NH₃)₂]₂NO₃, structure 1 above, was synthesized in the following manner.

To a solution of 1 mmol of trans-[PtCl₂(NH₃)₂] in 25 ml of anhydrous DMF was added 0.170 g (1 mmol) of AgNO₃. After stirring this mixture at room temperature for 16 hours, the precipitated AgCl was filtered off through a celite pad. To the filtrate was added 0.179 g (1 mmol) of 9-ethylguanine, and the mixture was allowed to stir for 12 hours. The DMF was removed under reduced pressure at 30°C. After addition of 50 mL of diethyl ether, the remaining oil solidified. The obtained crude product was recrystallized from methanol to give 0.380 g (white needles, yield 75%). The trans[PtCl(9-ethylguanine-N7)(NH₃)₂]₂NO₃ product was confirmed by NMR spectroscopy and elemental analysis.

Example 2:

Trans[PtCl(9-ethylguanine-N7)(NH₃)(quinoline)]NO₃, structure 2

WO 99/64019

PCT/US99/13112

10

above, was synthesized in the following manner.

A starting material, trans-[PtCl₂(NH₃)(quinoline)] was prepared according to the method of Van Beusichem et al., *Inorg. Chem.*, 1992, 31, 634. To a solution of 1 mmol of trans-[PtCl₂(NH₃)(quinoline)] in 25 ml of anhydrous DMF was added 0.170 g (1 mmol) of AgNO₃. After stirring this mixture at room temperature for 48 hours, the precipitated AgCl was filtered off through a celite pad. To the filtrate was added 0.179 g (1 mmol) of 9-ethylguanine, and the mixture was allowed to stir for 30 hours. The DMF was removed under reduced pressure at 30°C. After addition of 50 mL of diethyl ether, the remaining oil solidified. The obtained crude product was recrystallized from methanol to give 0.410 g (white needles, yield 66%). The trans[PtCl(9-ethylguanine-N7)(NH₃)(quinoline)]NO₃ product was confirmed by NMR spectroscopy and elemental analysis.

Example 3:

Studies were performed to investigate the anti-HIV effects of the platinum complex compound made in Example 2 above. More specifically, the anti-viral activity of this compound was evaluated *in vitro* for the HIV virus according to the standard protocols established by the National Cancer Institute for prospective anti-HIV agents. A separate non-treated culture was used as a control for these investigations.

The procedure used in the National Cancer Institute's test for agents active against human immunodeficiency virus is designed to detect agents acting at any stage of the virus reproductive cycle. The assay basically involves the killing of T4 lymphocytes by HIV. Small amounts of HIV are added to cells, and two cycles of virus reproduction are necessary to obtain the required cell killing. Agents that interact with virions, cells, or virus gene products to interfere with viral activities will protect cells from cytolysis. All tests compared with at least one positive (e.g., AZT-treated) control done at

the same time under identical conditions. The procedure used herein is outlined below:

- 5
- 10
- 15
- 20
- 25
1. Candidate agent (i.e., platinum complex of this invention) is dissolved in DMSO then diluted 1:100 in cell culture medium before preparing serial half-log dilutions. T4 lymphocytes (CEM cell line) are added and after a brief interval HIV-1 is added, resulting in a 1:200 final dilution of the compound. Uninfected cells with the compound serve as a toxicity control, and infected and uninfected cells without the compound server as basic controls.
 2. Cultures are incubated at 37°C in a 5% carbon dioxide atmosphere for six days.
 3. The tetrazolium salt, XTT, is added to all wells, and cultures are incubated to allow formazan color development by viable cells.
 4. Individual wells are analyzed spectrophotometrically to quantitate formazan production, and, in addition, are viewed microscopically for detection of viable cells and confirmation of protective activity.
 5. Drug-treated virus-infected cells are compared with drug-treated non-infected cells and with other appropriate controls (untreated infected and untreated non-infected cells, drug containing wells without cells, etc.) on the same plate.

The results are set forth in Table 1 below, and they are also graphically shown in FIG. 1.

Table 1

Dose (molar)	Percent of Protection	Percent of Control	
		Infected	Uninfected
6.35 x 10 ⁻⁸	-1.68	5.44	97.25
2.00 x 10 ⁻⁷	0.63	7.59	96.10
6.34 x 10 ⁻⁷	1.71	8.59	94.39

WO 99/64019

PCT/US99/13112

12

5

2.00 x 10 ⁻⁶	3.10	9.88	100.11
6.33 x 10 ⁻⁶	0.73	7.68	96.29
2.00 x 10 ⁻⁵	12.74	18.85	98.11
6.32 x 10 ⁻⁵	58.91	61.79	107.84
2.00 x 10 ⁻⁴	69.28	71.43	75.11

10

It is apparent from the results that the presence of the platinum coordination compound provided a significant level of protection of the cells against infection by HIV. These results are also suggestive that the platinum compounds of the present invention will be effective against many other types of viral infectants (e.g., influenza, hepatitis, papilloma, etc.).

15

While the invention has been described in terms of its preferred embodiments, those skilled in the art will recognize that the invention can be practiced with modification within the spirit and scope of the appended claims.

WO 99/64019

PCT/US99/13112

CLAIMS

We claim:

1 1. A method for treating a patient afflicted with a viral infection,
2 comprising administering to said patient an effective anti-viral amount of a
3 platinum coordination compound of the formula
4 [PtXA_mB_{3-m}]
5 where m ranges from 0 to 3,
6 where X is an anionic ligand,
7 where A is a substituent selected from the group consisting of NH₃,
8 secondary and tertiary amines substituted with alkyl moieties, and substituted
9 or unsubstituted heterocyclic amines, and in the case of more than one A
10 substituent the substituents may be the same or different, and
11 where B is selected from the group consisting of NH₃ and a heterocyclic
12 nucleobase with a nitrogen in a ring which is connected to Pt, and in the case
13 of more than one B substituent the substituents may be the same or different.

1 2. The method of claim 1 wherein said viral infection is HIV.

1 3. The method of claim 1 wherein said effective antiviral amount ranges
2 from about 0.1 mg/kg body weight/24 hr./patient to about 500 mg/kg body
3 weight/24 hr./patient.

1 4. The method of claim 1 wherein said step of administration is performed
2 by parenteral administration.

1 5. The method of claim 1 wherein X is trans to B.

1 12. A platinum coordination compound of the formula
2 $[PtXA_mB_{3-m}]$
3 where m ranges from 0 to 3,
4 where X is an anionic ligand,
5 where A is a substituent selected from the group consisting of NH_3 ,

WO 99/64019

PCT/US99/13112

15

6 secondary and tertiary amines substituted with alkyl moieties, and substituted
7 or unsubstituted heterocyclic amines, and in the case of more than one A
8 substituent the substituents may be the same or different, and
9 where B is selected from the group consisting of NH₃ and a heterocyclic
10 nucleobase with a nitrogen in a ring which is connected to Pt, and in the case
11 of more than one B substituent the substituents may be the same or different.

1 13. The platinum coordination compound of claim 12 wherein B is a
2 heterocyclic nucleobase selected from the group consisting of purine, purine
3 type compounds, pyrimidines, pyrimidine derivatives, nucleosides,
4 nucleotides, oligonucleotides and polynucleotides.

1 14. The platinum coordination compound of claim 12 wherein X is selected
2 from the group consisting of halogens, NO₃, ClO₄, hydroxyls, sulfhydryls,
3 OR and SR where R is a C₁₋₁₂ alkyl.

1 15. The platinum coordination compound of claim 12 selected from the
2 group consisting of trans[PtCl(9-ethylguanine-N7)(NH₃)₂]NO₃, and
3 trans[PtCl(9-ethylguanine-N7)(NH₃)(quinoline)].

1 16. The platinum coordination compound of claim 12 wherein said B is a
2 heterocyclic amine.

1 17. The method of claim 16 wherein said heterocyclic amine is selected from
2 the group consisting of substituted and unsubstituted thiazoles,
3 benzothiazoles, imidazoles, isoquinolines, quinolines, oxazole, indoles, and
4 acridines.




FIG.1

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/13112

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :A61K 33/24
US CL :424/649; 514/492

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/405, 408, 409, 418, 421, 649; 514/492

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 4,053,587 A (DAVIDSON et al) 11 October 1997. See examples and columns 1-4.	1-17
Y	US 5,093,134 A (MURRER et al) 03 March 1992. See column 4.	1-17
X	Database HCAPLUS, Accession No. 1998:6040, NEAMATI et al.	1, 12-14, 16
---	'Potent inhibitors of human immunodeficiency virus type 1 integrase:	-----
Y	identification of a novel four-point pharmacophore and tetracyclines as novel inhibitors', abstract, Mol. Pharmacol. (1997), 52(6), 1041-1055, see entire abstract.	1-17

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*G* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

22 JULY 1999

Date of mailing of the international search report

05 NOV 1999

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

NEIL LEVY CV

Telephone No. (703) 308-1235

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/i3112

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	Database HCAPLUS, Accession No. 1998:350081, BALCAROVA et al. 'DNA Interactions of a novel platinum drug, cis - [PtCl(NH3)2(N7-acyclovir)]+', abstract, Mol. Pharmacol. (1998), 53(5), 846-855, see entire abstract.	1-17
X --- Y	Database HCAPLUS, Accession No. 1987:611477, SYNDER et al. 'The in vitro and in vivo efficacy of cisplatin and analogs in the treatment of herpes simplex virus ii infections', abstract, J. Antimicrob. Chemother. (1987), 19(6), 815-22, see entire abstract.	1, 3-8, 10-14, 16, 17 ----- 1-17
X --- Y	Database HCAPLUS, Accession No. 1991:441284, HOLLIS et al. 'Mechanistic studies of a novel class of trisubstituted platinum (II) antitumor agents', abstract, Cancer Res. (1991), 51(7), 1866-75, see entire abstract.	1, 5-8, 10-14, 16 ----- 1-17
X --- Y	Database HCAPLUS, Accession No. 1996:45553, COLUCCIA et al. 'Platinum (II)-Acyclovir complexes: synthesis, antiviral and antitumor activity', abstract, MET.-BASED DRUGS (1995), 2(5), 249-56, see entire abstract.	1, 5-8, 10-14, 16 ----- 1-17